Key statistics
| Open | 104.00 |
|---|---|
| High | 104.00 |
| Low | 98.00 |
| Bid | 0.505 |
| Offer | 0.56 |
| Previous close | 101.00 |
| Average volume | -- |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Jan 06 2023.
More ▼
Announcements
- Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
- Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
- Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
- Can-Fite Provides Update on Clinical and Financial Status
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
- Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
- Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
- Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
- Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
More ▼
